Brief: Instil Bio Announces US FDA Clearance Of Investigational New Drug (Ind) Application For Axn-2510
02/07/2025 11:57
July 2 (Reuters) - Instil Bio Inc TIL.O: INSTIL BIO ANNOUNCES U.S. F.D.A. CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AXN-2510, A PD-L1XVEGF BISPECIFIC ANTIBODY, FOR A PHASE 1 TRIAL IN RELAPSED/REFRACTORY SOLID TUMORS INSTIL BIO INC - TO INITIATE PHASE 1 TRIAL OF '2510 BEFORE END OF 2025 INSTIL BIO INC - INITIAL SAFETY AND EFFICACY RESULTS FROM PHASE 2 STUDY EXPECTED IN H2 2025 Source text: ID:nGNX50jP5t Further company coverage: TIL.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Instil Bio
See all newsInstil Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges
Brief: Instil Bio Q2 Basic EPS USD -0.63
Instil Bio, Inc. expected to post a loss of 43 cents a share - Earnings Preview
Instil Bio Q1 net loss narrows on lower R&D expenses